Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
PRINCETON, N.J., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted...
-
Immunotherapy Candidate for Pediatric Osteosarcoma, ADXS-cHER2, Delays Metastatic Disease and Prolongs Overall Survival in Canine Osteosarcoma Bivalent Lm-LLO Immunotherapies Demonstrate...
-
PRINCETON, N.J., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that a data analysis of its...
-
PRINCETON, N.J., Oct. 20, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that it has appointed David J....
-
PRINCETON, N.J., Oct. 15, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced preliminary data from its...
-
PRINCETON, N.J., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a cancer immunotherapy company, today announced that preclinical and clinical data highlighting the potential of its...
-
PRINCETON, N.J., Oct. 8, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the appointment of world renowned...
-
PRINCETON, N.J., Oct. 1, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that Dr. Robert Petit, its Chief...
-
PRINCETON, N.J., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing cancer immunotherapies, announced that ADXS-cHER2, its proprietary Lm-LLO...
-
PRINCETON, N.J., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced the completion of an End-of-Phase 2...